Thursday, 21 November 2024
  
Login

Australia's most trusted
source of pharma news

Thursday, 21 November 2024
News

GM influenza virus on the cards

Posted 19 November 2024 AM

Doherty Clinical Trials (DCT) has applied to the OGTR to conduct a first-in-human clinical trial using a genetically modified influenza virus to test the efficacy of potential vaccines and therapeutic drugs.

Using gene technology (reverse genetics), the recombinant human influenza virus A and B (including H1N1 and H3N2) will be similar to naturally circulating wild type seasonal influenza viruses.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (15)

Clinical & Medical, R&D (8)

Other (10)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.